Urteste S.A. (URT.WA)
PLN 80.8
(-2.42%)
PLN 80.8
(-2.42%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -5.73 Million PLN | -55.19% |
| 2022 | -3.57 Million PLN | -60.45% |
| 2021 | -2.3 Million PLN | -351.56% |
| 2020 | -1.2 Million PLN | -40.06% |
| 2019 | -363.94 Thousand PLN | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -2.19 Million PLN | -239.32% |
| 2024 Q2 | -283 Thousand PLN | 64.86% |
| 2023 Q4 | -229 Thousand PLN | 77.66% |
| 2023 Q1 | -1.25 Million PLN | -23.94% |
| 2023 Q2 | -1.56 Million PLN | -25.14% |
| 2023 Q3 | -1.02 Million PLN | 34.63% |
| 2023 FY | - PLN | -89.6% |
| 2022 Q1 | -951.86 Thousand PLN | -24.97% |
| 2022 FY | - PLN | -60.45% |
| 2022 Q4 | -1.01 Million PLN | -81.83% |
| 2022 Q3 | -556 Thousand PLN | 49.77% |
| 2022 Q2 | -1.1 Million PLN | -16.3% |
| 2021 Q4 | -761.66 Thousand PLN | -19.95% |
| 2021 Q3 | -635 Thousand PLN | -168.23% |
| 2021 Q2 | -236.73 Thousand PLN | 56.92% |
| 2021 Q1 | -549.55 Thousand PLN | 0.0% |
| 2021 FY | - PLN | -351.56% |
| 2020 Q2 | -234.34 Thousand PLN | 0.0% |
| 2020 FY | - PLN | -40.06% |
| 2019 FY | - PLN | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bioceltix S.A. | -13.22 Million PLN | 56.663% |
| BIOTON S.A. | 43.89 Million PLN | 113.056% |
| Captor Therapeutics Spolka Akcyjna | -64.76 Million PLN | 91.151% |
| Mabion S.A. | 58.31 Million PLN | 109.828% |
| Molecure S.A. | -25.5 Million PLN | 77.531% |
| NanoGroup S.A. | -7.87 Million PLN | 27.182% |
| Pharmena S.A. | 33.78 Million PLN | 116.966% |
| Poltreg S.A. | -11.65 Million PLN | 50.845% |
| Pure Biologics Spólka Akcyjna | -26.07 Million PLN | 78.023% |
| Ryvu Therapeutics S.A. | -81.04 Million PLN | 92.929% |
| Synthaverse S.A. | 15.34 Million PLN | 137.345% |